Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.
Abstract
Background The BEAUTIFUL study assessed the morbidity and mortality benefits of the heart rate-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery disease and left-ventricular dysfunction. We did a subanalysis of this placebo group to test the hypothesis that elevated resting heart rate at baseline is a marker for subsequent cardiovascular death and morbidity.Methods The association of baseline resting heart rate with cardiovascular outcomes was analysed using Cox proportional hazard models for groups with a heart rate of 70 beats per min (bpm) or greater (2693 patients) versus less than 70 bpm (2745 patients). Additional analyses were done with finer categorisation of heart rate, and with heart rate as a continuous variable.Findings After adjustment for baseline characteristics, patients with heart rates of 70 bpm or greater had increased risk for cardiovascular death (34%, p=0.0041), admission to hospital for heart failure (53%, p<0.0001), admission to hospital for myocardial infarction (46%, p=0.0066), and coronary revascularisation (38%, p=0.037). For every increase of 5 bpm, there were increases in cardiovascular death (8%, p=0.0005), admission to hospital for heart failure (16%, p<0.0001), admission to hospital for myocardial infarction (7%, p=0.052), and coronary revascularisation (8%, p=0.034). The analysis of fine-groupings of heart rate suggests that the increase in mortality and heart failure outcomes rises continuously above 70 bpm, whereas the relation is less pronounced for coronary outcomes. For heart failure outcomes, the predictive value of resting heart rate was stronger for earlier events than for later events.Interpretation In patients with coronary artery disease and left-ventricular systolic dysfunction, elevated heart rate (70 bpm or greater) identifies those at increased risk of cardiovascular outcomes, with a differential effect on outcomes associated with heart failure and outcomes associated with coronary events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Resting heart rate independently predicts CV events, including HHF and death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [53]
In the citing paper
“Elevated heart rate has been shown to be associated with increased risk of further cardiac events in those with established CVD.60,61”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [60]
In the citing paper
“In healthy populations, a high resting HR has been associated with an increased risk of coronary artery disease and all-cause death12 and is also well recognized as a predictor of adverse outcomes in patients with heart failure (HF)13.”
From Smart wearable devices in cardiovascular care: Where we are and how to move forward (2021) · cites this paper as [13]
Citations
Cites
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Chatzizisis, Y. S., Coskun, A. U., Jonas, M., Edelman, E. R., Feldman, C. L., & Stone, P. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.059 · Cited by 1,483
Heart rate and cardiovascular mortality: The Framingham study
Kannel, W. B., Kannel, C., Paffenbarger, R. S., & Cupples, L. A. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90666-1 · Cited by 1,290
Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function
Ingwall, J. S., & Weiss, R. G. (2004) · Circulation Research · doi:10.1161/01.res.0000137170.41939.d9 · Cited by 604
Lechat, P., Hulot, J.-S., Escolano, S., Mallet, A., Leizorovicz, A., Werhlen-Grandjean, M., Pochmalicki, G., & Dargie, H. (2001) · Circulation · doi:10.1161/01.cir.103.10.1428 · Cited by 525
Left Ventricular Muscle Mass and Elevated Heart Rate Are Associated With Coronary Plaque Disruption
Heidland, U. E., & Strauer, B. E. (2001) · Circulation · doi:10.1161/hc3801.096325 · Cited by 350
Kolloch, R., Legler, U. F., Champion, A., Cooper-DeHoff, R. M., Handberg, E., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms
Giannoglou, G. D., Chatzizisis, Y. S., Zamboulis, C., Parcharidis, G. E., Mikhailidis, D. P., & Louridas, G. E. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.08.077 · Cited by 235
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citation2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citationAuthors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citation
Metadata
- Authors
- Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R.
- Affiliations
- Royal Brompton Hospital (GB)
- University of Glasgow (GB)
- University of Ferrara (IT)
- Corresponding author
- Fox, Kim
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 372
- Issue
- 9641
- Pages
- 817-821
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2129134633
- Cited by
- 789
- References
- 24
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 27 · 2020: 32 · 2019: 41 · 2018: 30 · 2017: 51 · 2016: 58 · 2015: 59 · 2014: 60 · 2013: 68 · 2012: 74
- FWCI
- 46.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- resting heart rate, prognostic factors, coronary artery disease, left ventricular systolic dysfunction, cardiovascular mortality, heart failure hospitalization, myocardial infarction, coronary revascularization, ivabradine
- MeSH terms
- Ivabradine, Aged, Benzazepines, Cardiovascular Diseases, Coronary Disease, Female, Heart Rate, Humans, Male, Middle Aged, Prognosis, Risk Factors, Tachycardia, Proportional Hazards Models, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61171-x
- The paper
- Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008). Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)61171-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.